Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 14.3% during trading on Wednesday . The company traded as low as C$0.06 and last traded at C$0.06. Approximately 140,000 shares were traded during mid-day trading, an increase of 44% from the average daily volume of 97,516 shares. The stock had previously closed at C$0.07.
Hemostemix Trading Up 8.3 %
The firm has a 50-day simple moving average of C$0.08 and a two-hundred day simple moving average of C$0.07. The company has a market capitalization of C$5.66 million, a price-to-earnings ratio of -3.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- What is the Dogs of the Dow Strategy? Overview and Examples
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- What Are Dividend Achievers? An Introduction
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
